TITLE

THE USE OF FIBRINOLYSIN IN NONHOSPITALIZED PATIENTS

AUTHOR(S)
Fillmore, A. James
PUB. DATE
May 1961
SOURCE
Angiology;May1961, Vol. 12 Issue 5, p174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents several cases of fibrinolysin in nonhospitalized patients with disease in the digestive organ. Effectiveness of combined fibrinolytic-anticoagulant therapy for the diagnosis of an 80-year old widow suffering from acute insufficiency of the basilar artery system; Significance of anticoagulant therapy in the diagnosis of a patient who developed milk-leg after pregnancy; Aid of the drug in treating a woman who developed thrombophlebitis of the left leg.
ACCESSION #
16430980

 

Related Articles

  • CLINICAL OBSERVATIONS IN THE TREATMENT OF PHLEBOTHROMBOSIS WITH FIBRINOLYSIN. Carroll, Bruce J. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p308 

    1. Fibrinolysin has been used in 82 patients without any deleterious occurrences. 2. An excellent response with appreciable shortening of hospital stay was obtained in 60 patients. A good response was obtained in 19 patients. Three patients had a poor response which might be attributed to a...

  • Prethrombotic State Due to Hypercoagulability in Patients with Permanent Transvenous Pacemakers. Ito, Tatsuo; Tanouchi, Jun; Kato, Junji; Nishino, Masami; Iwai, Kunimitsu; Tanahashi, Hideo; Hori, Masatsugu; Yamada, Yoshio; Kamada, Takenobu // Angiology;Oct1997, Vol. 48 Issue 10, p901 

    Venous thrombosis is a relatively usual but serious complication of permanent transvenous pacing. However, the pathogenesis bas not been defined. To clarify underlying abnormalities in the coagulation-fibrinolysis system in patients with permanent transvenous pacemakers, we measured serum levels...

  • Management of Anticoagulant and Thrombolytic Agents in Deep Venous Thrombosis. Coon, William W. // Vascular Surgery;Jan/Feb1982, Vol. 16 Issue 1, p1 

    Presents a study on the management of anticoagulant and thrombolytic agents in deep venous thrombosis. Utilization of the heparin agent in treating the disease; Treatment with oral anticoagulants; Use of thrombolytic agents.

  • Guidelines advise on thrombotic events in urology. Tennant, Scott // Urology Times;1/1/2005, Vol. 33 Issue 1, p4 

    Reports on the American College of Chest Physicians' "Guidelines on Antithrombotic and Thrombolytic Therapy". Risk factors for venous thromboembolism in urologic surgery patients; Mechanical thromboprophylaxis modalities; Comparison between mechanical methods of prophylaxis and anticoagulant...

  • FIBRINOLYTIC THERAPY IN ACUTE DEEP THROMBOPHLEBITIS. Moser, Kenneth M.; Hajjar, George C.; Sulavik, Stephen B. // Angiology;May1961, Vol. 12 Issue 5, p195 

    Reports on the diagnosis of acute deep venous thrombosis by fibrinolytic therapy. Advantages of using the drug to grant rapid relief of acute signs and symptoms of the disease; Efficacy of fibrinolytic agents; Consideration of the relationship between the alterations in crating parameters of...

  • Piyavit from the Medicinal Leech Is a New Orally Active Anticoagulating and Antithrombotic Drug. Baskova, Isolda P.; Korostelev, Alexander N.; Chirkova, Lidiya D.; Zavalova, Ludmila L.; Basanova, Angelica V.; Doutremepuich, Christian // Clinical & Applied Thrombosis/Hemostasis;Jan1997, Vol. 3 Issue 1, p40 

    Piyavit, a novel pharmacological preparation allowed in Russia as an oral antithrombotic drug for clinical use. contains medicinal leech saliva as the main source of biologically active substances that inhibit platelet-vascular and plasmic hemostasis and provide thrombolysis. It is shown that...

  • CLINICAL OBSERVATIONS IN THROMBOEMBOLIC DISEASE TREATED WITH FIBRINOLYSIN. Moser, Kenneth M. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p319 

    Describes experiences in the treatment of venous and arterial thrombotic disease using fibrinolysin. Ability of the anticoagulant drugs to provide a satisfactory degree of protection against the development of thrombosis; Factors determining response to fibrinolysin; Dependency of the therapy...

  • Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Yoon, J-H; Min, W-S; Kim, H-Je; Kim, J-H; Shin, S-H; Yahng, S-A; Lee, S-E; Cho, B-S; Eom, K-S; Kim, Y-J; Lee, S; Min, C-K; Cho, S-G; Kim, D-W; Lee, J-W; Park, C-W // Bone Marrow Transplantation;Dec2013, Vol. 48 Issue 12, p1562 

    Hepatic veno-occlusive disease (VOD) remains one of the most severe complications of hematopoietic SCT (HSCT). Anticoagulation and thrombolytic therapies using tissue-plasminogen activator (t-PA) have been used, but are reported to be ineffective and are associated with significant bleeding...

  • Mechanism of Rethrombosis After Thrombolytic Therapy: Angioscopic Findings and Investigation of the Coagulation System in Dogs. Maki, Akira; Shirato, Chiaki; Ohguchi, Masahisa; Aoki, Nobuo; Ochiai, Nobuhiko; Taguchi, Shigeru; Aoki, Isao; Ishikawa, Kyozo // Angiology;Jun1998, Vol. 49 Issue 6, p447 

    The purpose of this study was to angioscopically observe the process of thrombolysis after intracoronary administration of thrombolytic agents and to investigate the effects of these agents on coagulation/fibrinolysis systems in dogs. The coronary endothelium was removed and thrombus formation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics